Real-World Safety and Effectiveness of an 8-Week Regimen of Glecaprevir/Pibrentasvir in Patients with Hepatitis C and Cirrhosis

ConclusionAn 8-week regimen of GLE/PIB is well tolerated and highly effective among US patients with HCV and cirrhosis receiving routine clinical care.

http://link.springer.com/10.1007/s12325-023-02748-y

Source: Advances in Therapy - January 2, 2024 Category: Drugs & Pharmacology Source Type: research